دورية أكاديمية
أعرض في EDS

Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study

التفاصيل البيبلوغرافية
العنوان: Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
المؤلفون: Yasunori Murata, MD, PhD, Shigeru Tanzawa, MD, PhD, Toshihiro Misumi, PhD, Hiroshige Yoshioka, MD, PhD, Eisaku Miyauchi, MD, PhD, Kiichiro Ninomiya, MD, PhD, Masafumi Takeshita, MD, PhD, Kensaku Ito, MD, PhD, Tatsuro Okamoto, MD, PhD, Shunichi Sugawara, MD, PhD, Yosuke Kawashima, MD, Kazuki Hashimoto, MD, Masahide Mori, MD, PhD, Akihiko Miyanaga, MD, PhD, Anna Hayashi, MD, Hisashi Tanaka, MD, PhD, Ryoichi Honda, MD, PhD, Masafumi Nojiri, MD, PhD, Yuki Sato, MD, Akito Hata, MD, Ken Masuda, MD, PhD, Toshiyuki Kozuki, MD, PhD, Takahisa Kawamura, MD, PhD, Takuji Suzuki, MD, PhD, Teppei Yamaguchi, MD, PhD, Kazuhiro Asada, MD, PhD, Satoshi Tetsumoto, MD, PhD, Hiroshi Tanaka, MD, PhD, Satoshi Watanabe, MD, PhD, Yukihiro Umeda, MD, PhD, Kakuhiro Yamaguchi, MD, PhD, Shoichi Kuyama, MD, PhD, Kosuke Tsuruno, MD, PhD, Yuki Misumi, MD, PhD, Hiroshi Kuraishi, MD, PhD, Ken Yoshihara, MD, PhD, Akira Nakao, MD, PhD, Akihito Kubo, MD, PhD, Toshihiko Yokoyama, MD, PhD, Kana Watanabe, MD, PhD, Nobuhiko Seki, MD, PhD
المصدر: JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100593- (2023)
بيانات النشر: Elsevier, 2023.
سنة النشر: 2023
المجموعة: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: Necitumumab, Immune checkpoint inhibitor, Platinum rechallenge, Skin disorder, Lung squamous cell carcinoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Introduction: Necitumumab plus gemcitabine and cisplatin (GCN) is a standard therapy for patients with advanced lung squamous cell carcinoma (LSqCC). However, the efficacy and tolerability of GCN in second-line or later treatment for patients previously treated with immune checkpoint inhibitors (ICIs) remain unknown. Methods: This multicenter, retrospective, cohort study assessed the efficacy and tolerability of GCN initiated between November 1, 2019 and March 31, 2022 as second-line to fourth-line treatment in patients with advanced LSqCC who had been pretreated with ICIs. The primary end point was progression-free survival (PFS). Results: A total of 93 patients from 35 institutions in Japan were enrolled. The median PFS, median overall survival (OS), and objective response rate were 4.4 months (95% confidence interval [CI]: 3.8–5.3), 13.3 months (95% CI: 9.6–16.5), and 27.3% (95% CI: 18.3–37.8), respectively. The median PFS, median OS, and objective response rate for second-line, third-line, and fourth-line treatment groups were 4.8 months, 3.8 months, and 4.3 months (p = 0.24); 15.7 months, 11.6 months, and 10.1 months (p = 0.06); and 31.0%, 13.6%, and 37.5% (p = 0.22), respectively. The severity of GCN-related skin disorders was associated with longer PFS (p < 0.05) and OS (p < 0.05). The frequencies of grade ≥3 skin disorders, hypomagnesemia, pneumonitis, and febrile neutropenia were 16.1%, 7.5%, 1.1%, and 4.3%, respectively. There were no treatment-related deaths. Conclusions: GCN for ICI-pretreated patients with LSqCC seems tolerable and offers promising efficacy regardless of treatment line, and ICI pretreatment might enhance GCN efficacy.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2666-3643
العلاقة: http://www.sciencedirect.com/science/article/pii/S2666364323001364Test; https://doaj.org/toc/2666-3643Test
DOI: 10.1016/j.jtocrr.2023.100593
الوصول الحر: https://doaj.org/article/0e1d4e104d1e4f01bd75edf40b9e925cTest
رقم الانضمام: edsdoj.0e1d4e104d1e4f01bd75edf40b9e925c
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:26663643
DOI:10.1016/j.jtocrr.2023.100593